NYSE:EBS

Emergent BioSolutions Competitors

$82.83

+2.42 (+3.01 %)

(As of 11/27/2020 12:00 AM ET)

Add

Compare

Today's Range

$80.68

Now: $82.83▼

$82.98

50-Day Range

$79.17

MA: $92.46▼

$111.47

52-Week Range

$46.37

Now: $82.83▼

$137.61

Volume276,544 shs

Average Volume643,144 shs

Market Capitalization$4.39 billion

P/E Ratio26.63

Dividend YieldN/A

Beta1.44

Emergent BioSolutions (NYSE:EBS) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying EBS stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Emergent BioSolutions, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Emergent BioSolutions vs. Amgen Stock

Emergent BioSolutions (NYSE:EBS) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 71.7% of Amgen shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Valuation & Earnings

This table compares Emergent BioSolutions and Amgen's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent BioSolutions	$1.11 billion	3.97	$54.50 million	$2.91	28.46
Amgen	$23.36 billion	5.60	$7.84 billion	$14.82	15.17

Amgen has higher revenue and earnings than Emergent BioSolutions. Amgen is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent BioSolutions and Amgen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent BioSolutions	12.50%	26.68%	12.70%
Amgen	29.42%	95.55%	15.52%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Amgen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent BioSolutions	0	2	5	0	2.71
Amgen	1	12	15	0	2.50

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Amgen has a consensus price target of $254.08, indicating a potential upside of 13.02%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than Emergent BioSolutions.

Summary

Amgen beats Emergent BioSolutions on 9 of the 14 factors compared between the two stocks.

Emergent BioSolutions vs. Gilead Sciences Stock

Emergent BioSolutions (NYSE:EBS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 77.9% of Gilead Sciences shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Valuation & Earnings

This table compares Emergent BioSolutions and Gilead Sciences' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent BioSolutions	$1.11 billion	3.97	$54.50 million	$2.91	28.46
Gilead Sciences	$22.45 billion	3.35	$5.39 billion	$6.14	9.78

Gilead Sciences has higher revenue and earnings than Emergent BioSolutions. Gilead Sciences is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent BioSolutions and Gilead Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent BioSolutions	12.50%	26.68%	12.70%
Gilead Sciences	5.48%	37.77%	12.76%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Gilead Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent BioSolutions	0	2	5	0	2.71
Gilead Sciences	2	15	10	0	2.30

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Gilead Sciences has a consensus price target of $76.1538, indicating a potential upside of 26.86%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Emergent BioSolutions.

Summary

Gilead Sciences beats Emergent BioSolutions on 9 of the 14 factors compared between the two stocks.

Emergent BioSolutions vs. Vertex Pharmaceuticals Stock

Emergent BioSolutions (NYSE:EBS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Valuation & Earnings

This table compares Emergent BioSolutions and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent BioSolutions	$1.11 billion	3.97	$54.50 million	$2.91	28.46
Vertex Pharmaceuticals	$4.16 billion	14.16	$1.18 billion	$4.29	52.85

Vertex Pharmaceuticals has higher revenue and earnings than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent BioSolutions and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent BioSolutions	12.50%	26.68%	12.70%
Vertex Pharmaceuticals	38.51%	28.55%	20.68%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Vertex Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent BioSolutions	0	2	5	0	2.71
Vertex Pharmaceuticals	0	8	22	1	2.77

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Vertex Pharmaceuticals has a consensus price target of $290.5862, indicating a potential upside of 28.18%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Emergent BioSolutions.

Summary

Vertex Pharmaceuticals beats Emergent BioSolutions on 13 of the 15 factors compared between the two stocks.

Emergent BioSolutions vs. Regeneron Pharmaceuticals Stock

Emergent BioSolutions (NYSE:EBS) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Valuation & Earnings

This table compares Emergent BioSolutions and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent BioSolutions	$1.11 billion	3.97	$54.50 million	$2.91	28.46
Regeneron Pharmaceuticals	$7.86 billion	6.98	$2.12 billion	$21.47	23.94

Regeneron Pharmaceuticals has higher revenue and earnings than Emergent BioSolutions. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent BioSolutions and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent BioSolutions	12.50%	26.68%	12.70%
Regeneron Pharmaceuticals	37.30%	26.71%	19.39%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Regeneron Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent BioSolutions	0	2	5	0	2.71
Regeneron Pharmaceuticals	0	10	13	1	2.63

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Regeneron Pharmaceuticals has a consensus price target of $628.52, indicating a potential upside of 22.27%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Emergent BioSolutions.

Summary

Regeneron Pharmaceuticals beats Emergent BioSolutions on 11 of the 15 factors compared between the two stocks.

Emergent BioSolutions vs. Biogen Stock

Emergent BioSolutions (NYSE:EBS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 78.9% of Biogen shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

Valuation & Earnings

This table compares Emergent BioSolutions and Biogen's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent BioSolutions	$1.11 billion	3.97	$54.50 million	$2.91	28.46
Biogen	$14.38 billion	2.61	$5.89 billion	$33.57	7.26

Biogen has higher revenue and earnings than Emergent BioSolutions. Biogen is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emergent BioSolutions and Biogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent BioSolutions	12.50%	26.68%	12.70%
Biogen	35.63%	51.00%	23.54%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Biogen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent BioSolutions	0	2	5	0	2.71
Biogen	5	15	13	0	2.24

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Biogen has a consensus price target of $305.9032, indicating a potential upside of 25.48%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Emergent BioSolutions.

Summary

Biogen beats Emergent BioSolutions on 9 of the 14 factors compared between the two stocks.

Emergent BioSolutions vs. Seagen Stock

Emergent BioSolutions (NYSE:EBS) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Valuation & Earnings

This table compares Emergent BioSolutions and Seagen's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent BioSolutions	$1.11 billion	3.97	$54.50 million	$2.91	28.46
Seagen	$916.71 million	33.26	$-158,650,000.00	($1.33)	-127.16

Emergent BioSolutions has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

73.0% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 92.0% of Seagen shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Comparatively, 31.1% of Seagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Emergent BioSolutions and Seagen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent BioSolutions	12.50%	26.68%	12.70%
Seagen	-25.17%	-18.32%	-15.49%

Analyst Ratings

This is a summary of current ratings and target prices for Emergent BioSolutions and Seagen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent BioSolutions	0	2	5	0	2.71
Seagen	1	6	11	1	2.63

Emergent BioSolutions presently has a consensus price target of $93.1667, indicating a potential upside of 12.48%. Seagen has a consensus price target of $176.75, indicating a potential upside of 4.51%. Given Emergent BioSolutions' stronger consensus rating and higher probable upside, research analysts plainly believe Emergent BioSolutions is more favorable than Seagen.

Volatility and Risk

Emergent BioSolutions has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Summary

Emergent BioSolutions beats Seagen on 10 of the 15 factors compared between the two stocks.